When it comes to triple therapy, the totality of the evidence strongly suggests “less is more”. While many practitioners have been quick to adopt dual antithrombotic therapy, it is important to consider the external validity of these trials and how we apply them to our patients. In this blog, Dr. Noel offers 3 considerations that require careful reflection before throwing in the towel on triple therapy.
Share this post:Author: Brent N. Reed, PharmD, BCPS-AQ Cardiology, FAHA About five years ago, I wrote a post on the approach we used at my prior institution to desensitize patients to aspirin. In the time since then, I’ve received several
In this quick read, we provide an argument for why atenolol should be avoided in patients with compelling indications for beta blocker therapy.
Beta blockers remain a cornerstone in the management of several cardiovascular disorders yet many clinicians are reluctant to use them in the setting of cocaine abuse. In this entry, we take a look at the evidence.
Given the extensive role that platelet activation and aggregation play in the pathophysiology of acute coronary syndromes, it seems reasonable to administer a P2Y12 inhibitor as early as possible to minimize thrombus formation and progression of ischemia. Nonetheless, there remains considerable controversy surrounding the optimal timing of P2Y12 inhibitor administration in those undergoing percutaneous coronary intervention. In this blog, we’ll explore the data for and against early P2Y12 inhibitor administration in those presenting with non-ST-segment-elevation acute coronary syndromes and how coronary artery bypass graft surgery should, or should not, impact the decision for when to administer P2Y12 inhibitors.